MGLL and Alzheimer disease: It is thus plausible that AD-related upregulation of MAGL – initiating a downregulation of 2-AG availability – results in a compensatory upregulation of CB1 receptors and is therefore responsible for the increase in CB1 receptor density seen in the initial stages of AD.